Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

BackgroundThe usual treatment option for HER2 breast cancer is targeted therapy with trastuzumab. The common adverse effects of trastuzumab treatment are thrombocytopenia, however, acute thrombocytopenia is rare and its mechanism is still largely unknown.Case presentationWe reported a patient who pr...

Full description

Bibliographic Details
Main Authors:	Guoping Chen, Jianghua Ou, Jun Liu, Haoran Liao, Linwei Ding, Pingming Fan, Guankui Du
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Medicine
Subjects:	breast cancer HER2 trastuzumab dramatic thrombocytopenia complement response
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1037493/full

Similar Items

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report
by: Fangfang Gao, et al.
Published: (2023-05-01)

Prevalence of depression in junior and senior adolescents
by: Jing Zhang, et al.
Published: (2023-12-01)

The Effect of Whole-Grain Diet on the Gut Microbiota of the Elderly Individuals
by: Zeying Cui, et al.
Published: (2022-06-01)

Investigation of lipid-rich carcinoma of the breast
by: Gao Fangfang, Du Guankui, Wang Minjian, Fan Pingming
Published: (2024-01-01)

Effects of dog ownership on the gut microbiota of elderly owners.
by: Chaona Jiang, et al.
Published: (2022-01-01)

Effects of dog ownership on the gut microbiota of elderly owners
by: Chaona Jiang, et al.
Published: (2022-01-01)

Involvement of the complement system in immune thrombocytopenia: review of the literature
by: Risa Shindo, et al.
Published: (2023-10-01)

Chronically socially isolated mice exhibit depressive-like behavior regulated by the gut microbiota
by: Linwei Ding, et al.
Published: (2024-04-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

Olası Trastuzumab Kullanımına Bağlı Gelişen Pyojenik Granülom
by: Hilmi Cevdet Altınyazar, et al.
Published: (2013-01-01)

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features
by: Abraham Z. Cheloff, et al.
Published: (2020-07-01)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
by: Sarita Shrivastva, et al.
Published: (2023-07-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor
by: Katia Cortese, et al.
Published: (2023-05-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report
by: Yurou Xing, et al.
Published: (2024-01-01)

Intestinal transcriptional profiling reveals fava bean-induced immune response in DBA/1 mice
by: Guankui Du, et al.
Published: (2019-03-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells
by: Hamid Maadi, et al.
Published: (2022-12-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Development and evaluation of 89Zr-trastuzumab for clinical applications
by: Fatemeh Mohammadpour-Ghazi, et al.
Published: (2023-06-01)

Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome
by: Sallée Marion, et al.
Published: (2013-01-01)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
by: Xiaoyun Liu, et al.
Published: (2022-09-01)

Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer
by: Hiroaki Yamane, et al.
Published: (2024-03-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations
by: Zhenya Du, et al.
Published: (2024-03-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
by: Karam Irene, et al.
Published: (2013-01-01)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
by: Zhen-hao Wang, et al.
Published: (2022-10-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

In Vitro and In Vivo Effects of the Combination of Polypurine Reverse Hoogsteen Hairpins against HER-2 and Trastuzumab in Breast Cancer Cells
by: Ester López-Aguilar, et al.
Published: (2023-04-01)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
by: Joseph Tintelnot, et al.
Published: (2023-10-01)

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
by: Eurydice Angeli, et al.
Published: (2024-04-01)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
by: Orianne de la Brassinne Bonardeaux, et al.
Published: (2023-10-01)

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01)

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
by: Qiyun Shi, et al.
Published: (2023-12-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)